Manifestations and complications of rotavirus-positive gastroenteritis and rotavirus-negative gastroenteritis in preschool children
Abstract
Background. The cumulative annual statistics of rotavirus-associated gastroenteritis are about 25 million outpatient visits, 2 million hospitalizations, and 180,000–450,000 deaths in children under 5 years of age.
Aim: To analyze the manifestations and complications of rotavirus compared with non-rotavirus gastroenteritis in UK children.
Materials and methods. A retrospective hospital-based case-control study was conducted at three sites in East London, Great Britain. Cases were children aged 1 month to 16 years who were diagnosed with acute gastroenteritis between June 1, 2011, and December 31, 2013, and who were positive for rotavirus by PCR (polymerase chain reaction) on stool virology. They were compared by age, gender and month of referral to a control group with rotavirus-negative gastroenteritis.
Results. Data were collected from 116 children (50 cases and 66 controls). Children with rotavirus gastroenteritis were more likely to have metabolic acidosis (pH 7.30 vs. 7.37) and fever (74% vs. 46%) and were more likely to require hospitalization compared with children with non-rotavirus gastroenteritis. (93% vs. 73%). Neurological complications were the most common extraintestinal manifestations, but did not differ significantly between children with rotavirus-positive gastroenteritis (RPG) and rotavirus-negative gastroenteritis (RNG) (24% vs. 15%, respectively). Encephalopathy occurred only in children with rotavirus infection.
Conclusion. Therefore, rotavirus is an…
How strong is the evidence?
Evidence Hub reads this as a case-control, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 450,000 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.